-$0.10 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter

Brokerages expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.08). Sunesis Pharmaceuticals reported earnings of ($0.20) per share during the same quarter last year, which indicates a positive year over year growth rate of 50%. The company is expected to issue its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.37). For the next year, analysts expect that the company will report earnings of ($0.29) per share, with EPS estimates ranging from ($0.67) to $0.48. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.08.

A number of research analysts recently issued reports on the stock. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 4th. HC Wainwright reissued a “hold” rating and set a $0.50 price target on shares of Sunesis Pharmaceuticals in a research note on Tuesday, March 12th. Finally, Oppenheimer set a $6.00 target price on shares of Sunesis Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, March 8th.

Several institutional investors and hedge funds have recently bought and sold shares of SNSS. Aisling Capital Management LP bought a new stake in Sunesis Pharmaceuticals during the fourth quarter valued at about $1,092,000. Algert Global LLC purchased a new position in shares of Sunesis Pharmaceuticals in the first quarter worth about $25,000. BlackRock Inc. raised its stake in shares of Sunesis Pharmaceuticals by 27.2% in the first quarter. BlackRock Inc. now owns 219,135 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 46,852 shares during the last quarter. Fosun International Ltd purchased a new position in shares of Sunesis Pharmaceuticals in the first quarter worth about $863,000. Finally, Wells Fargo & Company MN raised its stake in shares of Sunesis Pharmaceuticals by 1,486.5% in the first quarter. Wells Fargo & Company MN now owns 939,958 shares of the biopharmaceutical company’s stock worth $1,143,000 after purchasing an additional 880,711 shares during the last quarter. 43.10% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:SNSS traded down $0.07 during midday trading on Friday, hitting $0.71. The stock had a trading volume of 52,945 shares, compared to its average volume of 679,589. The stock has a market capitalization of $54.40 million, a PE ratio of -0.99 and a beta of 2.98. Sunesis Pharmaceuticals has a fifty-two week low of $0.20 and a fifty-two week high of $2.87.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Further Reading: What are catch-up contributions?

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.